EUVIMEDEUVIMED entdecken
Systematische Übersicht

Unraveling the rationale and conducting a comprehensive assessment of KD025 (Belumosudil) as a candidate drug for inhibiting adipogenic differentiation—a systematic review

Sandra Maria Barbalho, Ricardo de Alvares Goulart, Giulia Minniti, Marcelo Dib Bechara, Marcela Vialogo Marques de Castro, Jefferson Aparecido Dias, Lucas Fornari Laurindo

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024

DOI: 10.1007/s00210-023-02834-6 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Sandra Maria Barbalho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, São Paulo, 17525-902, Brazil. Hauptthemen laut MEDLINE: Adipogenesis, rho-Associated Kinases, Heterocyclic Compounds, 4 or More Rings. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 168 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rho-associated kinases (ROCKs) are crucial during the adipocyte differentiation process. KD025 (Belumosudil) is a newly developed inhibitor that selectively targets ROCK2. It has exhibited consistent efficacy in impeding adipogenesis across a spectrum of in vitro models of adipogenic differentiation. Given the novelty of this treatment, a comprehensive systematic review has not been conducted yet. This systematic review aims to fill this knowledge void by providing readers with an extensive examination of the rationale behind KD025 and its impacts on adipogenesis. Preclinical evidence was gathered owing to the absence of clinical trials. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed, and the study's quality was assessed using the Joanna Briggs Institute (JBI) Checklist Critical Appraisal Tool for Systematic Reviews. In various in vitro models, such as 3T3-L1 cells, human orbital fibroblasts, and human adipose-derived stem cells, KD025 demonstrated potent anti-adipogenic actions. At a molecular level, KD025 had significant effects, including decreasing fibronectin (Fn) expression, inhibiting ROCK2 and CK2 activity, suppressing lipid droplet formation, and reducing the expression of proadipogenic genes peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer-binding protein α (C/EBPα). Additionally, KD025 resulted in the suppression of fatty acid-binding protein 4 (FABP4 or AP2) expression, a decrease in sterol regulatory element binding protein 1c (SREBP-1c) and Glut-4 expression. Emphasis must be placed on the fact that while KD025 shows potential in preclinical studies and experimental models, extensive research is crucial to assess its efficacy, safety, and potential therapeutic applications thoroughly and directly in human subjects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adipogenesisrho-Associated KinasesHeterocyclic Compounds, 4 or More RingsHumansAnimalsCell DifferentiationMiceAdipocytes1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineProtein Kinase Inhibitors

Stichwörter der Autor:innen

BelumosudilAdipocyte differentiationCasein kinaseKD025ROCK2Rho-associated kinase

Substanzen

rho-Associated KinasesKD0251-(5-Isoquinolinesulfonyl)-2-MethylpiperazineROCK2 protein, humanProtein Kinase InhibitorsHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, São Paulo, 17525-902, Brazil.
  • Postgraduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marília, São Paulo, 17525-902, Brazil.
  • Department of Biochemistry and Nutrition, School of Food and Technology of Marília (FATEC), Marília, São Paulo, 17500-000, Brazil.
  • Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, São Paulo, 17525-902, Brazil. lucasffffor@gmail.com.
  • Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de Marília (FAMEMA), Marília, São Paulo, 17519-030, Brazil. lucasffffor@gmail.com.

Zitieren

APA

Barbalho, S. M., de Alvares Goulart, R., Minniti, G., Bechara, M. D., de Castro, M. V. M., Dias, J. A., & Laurindo, L. F. (2024). Unraveling the rationale and conducting a comprehensive assessment of KD025 (Belumosudil) as a candidate drug for inhibiting adipogenic differentiation—a systematic review. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02834-6

Vancouver

Barbalho SM, de Alvares Goulart R, Minniti G, Bechara MD, de Castro MVM, Dias JA, et al. Unraveling the rationale and conducting a comprehensive assessment of KD025 (Belumosudil) as a candidate drug for inhibiting adipogenic differentiation—a systematic review. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-023-02834-6

BibTeX
@article{Barbalho2024,
  author = {Barbalho, Sandra Maria and de Alvares Goulart, Ricardo and Minniti, Giulia and Bechara, Marcelo Dib and de Castro, Marcela Vialogo Marques and Dias, Jefferson Aparecido and Laurindo, Lucas Fornari},
  title = {Unraveling the rationale and conducting a comprehensive assessment of KD025 (Belumosudil) as a candidate drug for inhibiting adipogenic differentiation—a systematic review},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  doi = {10.1007/s00210-023-02834-6}
}
Kostenlos starten →